Indication
Partial Response
1 clinical trial
3 products
Product
PlaceboClinical trial
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)Status: Active (not recruiting), Estimated PCD: 2024-12-30
Product
RucaparibProduct
Nivolumab